anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a traditional Chinese medicine for treating beriberi edema of women caused by wind-toxin, in particular to a wind-toxin beriberi medicine. Provides a medicine for solving the female beriberi by dispelling wind and removing dampness, inducing diuresis and reducing edema. The medicine for treating wind-poison beriberi comprises purple perilla, akebia stem, white mulberry root-bark, fennel, trifoliate orange, notopterygium root, doubleteeth pubescent angilica root, fineleaf schizonepeta herb, pawpaw, green tangerine orange peel, liquorice and areca seed. The perilla is stems and leaves of the perilla, the fennel is roots of the fennel, the schizonepeta is ears of the schizonepeta, and the trifoliate orange is trifoliate orange. The medicines are respectively ground into fine powder, 9 g of the fine powder is taken each time, 250 ml of water, 3 slices of ginger and one fistular onion stalk are decocted to 175 ml, and dregs are removed for warm taking. The medicine adopting the formula can solve beriberi which is accompanied by symptoms such as intra-abdominal congestion, phlegm and nausea, poor appetite, heavy feet, edema and the like besides beriberi for women by dispelling wind and removing dampness, and inducing diuresis to alleviate edema.
The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In embodiments, the liposomes deliver temozolomide across the blood-brain barrier for treatment of primary or metastatic brain tumors. Additional cancers that can be treated with the liposomes include neuroendocrine tumors, melanoma, prostate, head and neck, ovarian, lung, liver, breast, urogenital, gastric, colorectal, cervical, liposarcoma, rhabdomyosarcoma, choriocarcinoma, pancreatic, retinoblastoma and other types of cancer. In another embodiment the liposomes deliver melphalan for the treatment of multiple myeloma, other tumors of the blood or other solid tumors. In still other embodiments the liposomes can deliver other drugs, including atropine for treatment of organophosphate poisoning.
INTRODUCTION: To prevent blood donors from developing iron deficiency (ferritin <15 μg/L) and subsequent anemia (hemoglobin <120 g/L), blood services rely on information about known risk factors, including the donor's sex and age. For example, while Finnish women are able to donate whole blood with a minimum donation interval of 91 days, women in the 18 to 25-year-old age group are recommended to donate no more than once per year. Menstrual blood loss is not accounted for in blood donation interval recommendations, despite being a known risk factor of iron deficiency. We aim to investigate to what extent menstrual bleeding is associated with ferritin and hemoglobin levels in female blood donors, and quantify the association of other menstruation-related variables not currently accounted for by blood services (i.e., use of hormonal contraception, heavy menstrual bleeding) with iron deficiency or anemia.
MATERIAL AND METHODS: The study population consisted of 473 premenopausal and 491 postmenopausal Dutch whole blood donors. Exclusion criteria were current pregnancy, BMI ≥50, ferritin ≥200, pictorial blood assessment chart (PBAC) ≥400, and age <18 or ≥70 years. Menstrual blood loss was quantified using a PBAC, a semiquantitative method to evaluate the number of used menstrual products and the degree of staining. We identified predictors of log(ferritin)/hemoglobin and iron deficiency/anemia using Bayesian linear and logistic regression models and quantified the average percentage of variance in log(ferritin) and hemoglobin explained by the covariates.
RESULTS: Menstrual blood loss accounted for most of the explained variance in hemoglobin (8%) and second only to the number of days since last donation for ferritin (8%). Heavy menstrual bleeding (PBAC ≥150, OR = 3.56 [1.45-8.85], prevalence 13%) was associated with anemia, and use of levonorgestrel-releasing intrauterine device was negatively associated with iron deficiency (OR = 0.06 [0.01-0.44]). After statistical control for menstrual blood loss, age was not associated with iron status.
CONCLUSIONS: Menstrual blood loss and blood donation were the most important determinants of iron status in premenopausal women. Thus, results suggest that accounting for menstrual blood loss in donation interval guidelines may benefit blood donors.
Particular implementations are particularly useful in providing a system that allows the secure distribution of medical documents through a medical station.  In some implementations, the medical station includes a user interface and a camera that captures an image and attaches the image to a medical document. In order to receive a medical document through the system, a user requests a medical examination, enters information into the system by answering questions, and by using medical implements, and then requests the medical document. A picture of the customer or other patient is captured for attachment to the medical document. Another implementation allows a station user to communicate directly with a medical professional during the examination process through a medical interface on the station. Some particular implementations are configured as mobile medical stations.
Due to oral minocycline’s virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines. 

Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, pancreatitis, inflammatory lesions (with monilial overgrowth) in the anogenital region, and increases in liver enzymes have been reported. Rarely, hepatitis and liver failure have been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of esophagitis and esophageal ulcerations have been reported in patients taking the tetracycline-class antibiotics in capsule and tablet form. Most of these patients took the medication immediately before going to bed (see DOSAGE AND ADMINISTRATION).

Skin: Maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Fixed drug eruptions have been rarely reported. Lesions occurring on the glans penis have caused balanitis. Erythema multiforme and rarely Stevens-Johnson syndrome have been reported. Photosensitivity is discussed above (see WARNINGS). Pigmentation of the skin and mucous membranes has been reported. 

Renal toxicity: Elevations in BUN have been reported and are apparently dose related (see WARNINGS). Acute renal failure has been rarely reported and, in most cases, has been reversible.

Hypersensitivity reactions: Urticaria, angioneurotic edema, polyarthralgia, anaphylaxis, anaphylactoid purpura, pericarditis, exacerbation of systemic lupus erythematosus and rarely pulmonary infiltrates with eosinophilia have been reported. A lupus-like syndrome and serum sickness-like reactions have also been reported. 

Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported. 

Central nervous system: Bulging fontanels in infants and benign intracranial hypertension (pseudotumor cerebri) in adults (see PRECAUTIONS-General) have been reported. Headache has also been reported.

Other: When given over prolonged periods, tetracyclines have been reported to produce brownblack microscopic discoloration of the thyroid glands. Very rare cases of abnormal thyroid function have been reported. 

Tooth discoloration in pediatric patients less than 8 years of age (see WARNINGS) and also, rarely, in adults have been reported. 

Tinnitus and decreased hearing has been rarely reported in patients on minocycline hydrochloride.
The invention discloses a fallopia multiflora and radix rehmanniae liquor and preparation method thereof. The fallopia multiflora and radix rehmanniae liquor is prepared from 20-30g of fallopia multiflora preparata, 80-100g of radix rehmanniae preparata, 20-30g of polygonatum kingianum, 10-15g of ginseng, 10-15g of Chinese yam, a saussurea involucrata flower (about 2g) and 2000 ml of white liquor from pure grains. The employed medicines for preparing the fallopia multiflora and radix rehmanniae liquor includes the fallopia multiflora preparata, the radix rehmanniae preparata, the polygonatum kingianum, the ginseng, the Chinese yam, the saussurea involucrata flower and the white liquor from pure grains according to a reasonable proportion hereinabove. Functions of the medicines are depended on, are cooperated with and are synergized with each other so that the fallopia multiflora and radix rehmanniae liquor is high in health-caring effects when being compared with conventional fallopia multiflora liquor. The fallopia multiflora and radix rehmanniae liquor has effects of tonifying liver and boosting kidney, fortifying and reinforcing body and blackening hair. The fallopia multiflora and radix rehmanniae liquor is significant in curative effects on the deficiency of liver and kidney, soreness and weakness of waist and knees and early graying of hair.
PROBLEM TO BE SOLVED: To allow transmitting data of health conditions and the like without any operation. SOLUTION: In a signal transmission system, a wearable appliance 30 is contacted to a user 10 via an electrode 31. When the user uses a toilet, a transmission path 13 of liquid is formed between a human body and a toilet bowl 60. A main transmission path of signals is formed in such a route from the appliance 30, the electrode 31, the user (human body) 10 to an electrode 43 of the bowl 60, so that a return transmission path 12 is formed by a neighboring electromagnetic field. Thus, information is transferred between the appliance 30 and a personal computer 50. More specifically, the data of health conditions from a heartbeat sensor 39 and the like is transmitted to the computer 50.
Wnt-signaling pathway plays a crucial role in the pathogenesis and progression of Chronic Myeloid Leukemia (CML). sFRP1 is involved in the suppression of the Wnt-signaling pathway and has been shown to be epigenetically silenced by promoter hypermethylation during CML progression. DNMT3A plays a crucial role in promoter hypermethylation and is responsible for establishing methylation patterns. We aimed to analyze the relationship between sFRP1 expression and DNMT3A, TET1, TET2 and TET3 proteins that are responsible for maintaining cellular methylation patterns; along with miRNAs miR144-3p and miR-767-5p that are known to be associated with these proteins. CML cell lines K562 and K562S which stably expresses sFRP1, were used to compare the changes in miR144-3p and miR-767-5p expression. DNMT3A, TET1, TET2 and TET3 protein levels were analyzed by Western blot. In K562S cells the expression of miR-144-3p and miR-767-5p were decreased along with DNMT3A and TET1 protein levels. On the contrary, TET2 protein was increased. Our results support other reports involving sFRP1 and methylation dynamics; as well as opening new avenues of exploration. Our data supports the conclusion that re-expression of sFRP1 protein alters the expression of factors that play important roles in the overall methylation patterns in the leukemic cell line K562.
Low back pain (LBP) is a leading cause of global disabilities. Numerous molecular, cellular, and anatomical factors are implicated in LBP. Current issues regarding neurologic alterations in LBP have focused on the reorganization of peripheral nerve and spinal cord, but neural mechanisms of exactly what LBP impacts on the brain required further researches. Based on existing clinical studies that chronic pain problems were accompanying alterations in brain structures and functions, researchers proposed logical conjectures that similar alterations occur in LBP patients as well. With recent extensive studies carried out using noninvasive neuroimaging technique, increasing number of abnormalities and alterations has been identified. Here, we reviewed brain alterations including white matters, grey matters, and neural circuits between brain areas, which are involved in chronic LBP. Moreover, brain structural and functional connectivity abnormalities are correlated to the happening and transition of LBP. The negative emotions related to back pain indicate possible alterations in emotional brain regions. Thus, the aim of this review is to summarize current findings on the alterations corresponding to LBP in the brain. It will not only further our understanding of etiology of LBP and understanding of negative emotions accompanying with back pain but also provide ideas and basis for new accesses to the diagnosis, treatment, and rehabilitation afterward based on integral medicine.
Cystic fibrosis (CF) is a genetic disorder which is typically fatal during early adulthood, due to progressive bronchiectasis and respiratory failure. Chronic lung infection with Pseudomonas aeruginosa begins in early life and is clearly associated with decline (especially mucoid phenotypes), making this infection a major target of therapy. The inflammatory response to infection may also be dysregulated in CF, so that suppression of airway inflammation is a second major goal of therapy. However, "best practice" for treatment of Pseudomonas infection in early CF is not defined (several recently published commentaries available upon request) and is a critical issue currently in clinical management of CF. Inhaled tobramycin alone has been reported to be effective at short-term eradication of P. aeruginosa from bronchoalveolar lavage fluid (BALF) in children with cystic fibrosis (CF) age 3 mo-6 yr, but inflammation was unaffected by this treatment, and recurrence of infection occurred fairly quickly for mucoid strains. The ideal treatment would result in long-term reduction in both bacterial quantity and inflammation. Some bacteria in the CF airway may be both inaccessible to inhaled antibiotics, and "hidden" from BALF, by location in inspissated secretions, and P. aeruginosa may not be effectively eradicated in paranasal sinuses. Thus, it is reasonable to hypothesize that treatment with parenteral antibiotics provides better overall eradication of organisms and consequently reduced stimulus for ongoing or recurrent inflammation in the airways. We therefore propose a prospective, randomized clinical trial comparing the effects of these 2 modes of antibiotic treatment on BALF inflammation in young, P. aeruginosa-positive CF patients.
Minimal hepatic encephalopathy (MHE) is common in liver cirrhosis and is identified by psychometric tests. The portosystemic hepatic encephalopathy score (PHES) is the most widely used and serves as an inter-study comparator. PHES has not been standardised for use in the Danish population, where German normal values have been applied until now based on the notion that the populations are comparable. This study aimed to evaluate if German PHES normal values can be applied in the Danish population and establish Danish normal values if needed. 200 Danish and 217 German healthy persons underwent Number Connection Test A and B (NCT), Line Tracing Test (LTT), Digit Symbol Test (DST), and Serial Dotting Test (SDT), and based on performance, PHES was calculated. German and Danish PHES performance declined with age in all subtests but more rapidly in Danes. Both German and Danish norms were impacted by gender and education, but to a different extent in the single tests of the test battery. Accordingly, there was a need for specific Danish normal values, which are presented here. Applying the new Danish normal values instead of the German in patients with cirrhosis yielded a lower percentage of out-of-norm performances (58% vs. 66%) and, hence, a lower prevalence of MHE. Danes and Germans perform differently on PHES, and therefore, normal German values cannot be used in Danish patients. Danish normal values are presented here and yield a lower number of 'out of norm' performances.
Eighty-four CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus > 6 mg/dL) following a two-week phosphate binder washout period were randomized in a cross-over design to receive in random order sevelamer hydrochloride and active-control for eight weeks each. Treatment periods were separated by a two-week phosphate binder washout period. Patients started on treatment three times per day with meals. Over each eight-week treatment period, at three separate time points the dose of sevelamer hydrochloride could be titrated up to control serum phosphorus, the dose of active-control could also be altered to attain phosphorus control. Both treatments significantly decreased mean serum phosphorus by about 2 mg/dL (Table 6).

  


The distribution of responses is shown in Figure 3. The distributions are similar for sevelamer hydrochloride and active control. The median response is a reduction of about 2 mg/dL in both groups. About 50% of subjects have reductions between 1 and 3 mg/dL.

Figure 3. Percentage of patients (Y-axis) attaining a phosphorus reduction from baseline (mg/dL) at least as great as the value of the X-axis.

Average daily sevelamer hydrochloride dose at the end of treatment was 4.9 g (range of 0 to 12.6 g).
A composition for the treatment of bladder fibrosis in a patient in need that includes a miR-29 mimic is disclosed. The miR-29 mimic may include a working RNA strand with the nucleotide sequence UAGCACCAUCUGAAAUCGGUUUU (SEQ ID NO:4) and a passenger RNA strand comprising the nucleotide sequence: AACCGAUUUCuuuUGGUGCUAUU (SEQ ID NO:5). The passenger RNA strand includes a 2′-O-methylation modification to increase stability. Cholesterol is conjugated to the 3′-end of the passenger RNA strand to enhance cellular uptake. The composition may further include a carrier molecule including, but not limited to, branched polyethylenimine at an N/P ratio of 0.8, where N denotes the nitrogens of the polyethylenimine and P denotes the phosphate groups of the working and passenger RNA strands. In some aspects, the composition may be an injectable composition that includes a polyplex dissolved in a 0.5% glucose solution, where the polyplex is formed from the working and passenger RNA strands and the carrier molecule.
NGS can not only detect tissue samples, but also blood samples. For some inoperable cancer patients, the acquisition of tissue samples is difficult and traumatic. It is of great significance for the diagnosis and treatment of these patients to determine MSI status by blood testing. In addition, the heterogeneity of malignant tumors is usually strong, blood testing can overcome the heterogeneity of tissue, and can dynamically monitor the patient's condition. 50 patients with gastric cancer, duodenal cancer and small intestinal cancer will be enrolled in the study. Among them, 30 patients with MSI-H and 20 patients with MSS confirmed by IHC/PCR.The investigators will use 520 gene panel for NGS sequencing of tissue and blood samples from selected patients to study the sensitivity and specificity of NGS in detecting Microsatellite State in blood.
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to compounds of the formula (I)   or the formula (II)   where R 1  means N(R 10 )(R 11 ); R 2  means lower thioalkyl; each of R 3  and R 5  means independently CH 2  or C(O); R 4  means unsubstituted or substituted lower thioalkyl where CH 2 NHC(O)R 13  is a substituent and it is linked to the indicated thio-group; R 6  means a residue of heteroaromatic α-amino acid; R 7  means a residue of natural or synthetic α-amino acids; R 8  means OH or lower alkoxy-group or in common with R 7  it forms homoserine lactone; R 9  means H; each of R 10  and R 11  represents independently H; R 12  means unsubstituted or substituted fragment taken among aryl, aryl-lower alkyl where one or some lower alkyls or halogen atom are substituents; R 13  means lower alkyl; R 18  means H under condition that if R 4  means unsubstituted lower thioalkyl then free thio-groups from R 2  and R 4  can form disulfide bond; or its pharmaceutically acceptable salts. Compounds elicit ability to inhibit activity of prenyltransferases. Invention describes also pharmaceutical compositions comprising indicated compounds and method of inhibition of activity of prenyltransferase. EFFECT: valuable biochemical properties of compounds. 22 cl, 3 ex
The present application relates to the design and synthesis of prodrugs of novel positively charged polypeptides and related compounds having the structure of the general formula (1) 'Structure 1'. The compound represented by the general formula (1) 'Structure 1' can be prepared by standard polypeptide synthesis methods. The positively charged amino groups of the polypeptide prodrug molecule not only render the drug soluble in water, but also bind to the negative charge on the phosphate head group of the biofilm to push the drug into the cytoplasm. The lipophilic moiety in the prodrug molecule (by modification of the polar group with a lipophilic alkyl group) will facilitate entry of the drug into the skin membrane. Experimental results show that more than 40% of the prodrug can switch back to the parent peptide structure in a few minutes. The prodrug can even easily cross the blood brain barrier. Transdermal drug delivery systems for polypeptides and related compounds may enable the use of polypeptide hormones in the medical field. Another great benefit of transdermal administration of these prodrugs is that administration is more convenient, particularly to children.
FIELD: medicine. SUBSTANCE: method involves preliminarily taking biopsy samples as a piece of healthy skin epidermis to select a culture of living keratinocytes. Then, cosmetic hypotrophic cicatrix filing operation is carried out to basal epidermis layer and the preliminarily cooled dermal equivalent produced as a mixture of fibroblasts with collagen and growth medium taken in non-polymerized form to fill micro-relief of the filed hypotrophic cicatrix surface. After having polymerized the dermal equivalent, keratinocyte culture is arranged over the polymerized dermal equivalent surface. The keratinocyte culture is administered in particular cases as suspension. The keratinocyte culture is administered in particular cases as multilayer flat plates with no substrate. The keratinocyte culture is administered in particular cases as multilayer flat plates with substrate. EFFECT: enhanced effectiveness in removing and healing skin defects. 4 cl
Alzheimer's disease (AD) and more than twenty other dementias, termed tauopathies, are pathologically defined by insoluble aggregates of the microtubule-associated protein tau (MAPT). Although tau aggregation correlates with AD symptomology, the specific tau species, i.e., monomers, soluble oligomers, and insoluble aggregates that induce neurotoxicity are incompletely understood. We developed a light-responsive tau protein (optoTAU) and used viscosity-sensitive AggFluor probes to investigate the consequence(s) of tau aggregation in human neurons and identify modifiers of tau aggregation in AD and other tauopathies. We determined that optoTAU reproduces biological and structural properties of tau aggregation observed in human brains and the pathophysiological transition in tau solubility in live cells. We also provide proof-of-concept for the utilization of optoTAU as a pharmacological platform to identify modifiers of tau aggregation. These findings have broad implications for the characterization of aggregation-prone proteins and investigation of the complex relationship between protein solubility, cellular function, and disease progression.